• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device

December 5, 2019 By Danielle Kirsh

leo-portal-collabLeo Pharma and Portal Instruments this week announced a global collaboration and license agreement to develop a needle-free drug delivery system.

Through the agreement, Leo Pharma’s investigational and approved medicines will be used in combination with Portal’s needle-free drug delivery system.

Portal’s needle-free jet injector platform allows patients to self-administer biologics without needles. It features a reusable, software-controlled handheld injection device and a single-use, pre-filled cartridge to deliver medicine through a pressurized liquid jet, rather than a needle.

“Leo Pharma’s novel therapies in the field of medical dermatology combined with Portal’s innovative approach to drug administration offer hope to people living with debilitating skin diseases,” senior VP of global development at Leo Pharma Christian Antoni said in a news release. “It is our ambition that this collaboration will lead to new and easier ways for people with skin diseases to administer our treatments on their own in the comfort of their home with a needle-free solution.”

“We are excited at the prospect of working closely with Leo Pharma and support their ambition to empower people with skin diseases with a next-generation drug delivery platform for self-administration,” CEO of Portal Patrick Anquetil said. “This commercial collaboration gives us the opportunity to lead with innovation in the field of medical dermatology by combining novel medicines with a patient-preferred needle-free drug delivery system.”

Filed Under: Drug-Device Combinations, Research & Development Tagged With: Leo Pharma, portal instruments

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS